(Q46682546)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Roberto Cauda

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

S Di Giambenedetto

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

P Villani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

A Bacarelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

E Ragazzoni

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

M Regazzi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

P Navarra

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

1 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

239-245

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18366448%20AND%20SRC:MED&resulttype=core&format=json

In vitro antiviral interaction of lopinavir with other protease inhibitors

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

Therapeutic drug monitoring in the treatment of HIV-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

The metabolic effects of lopinavir/ritonavir in HIV-negative men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

Atazanavir: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

Predictors of virological response to atazanavir in protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

The private sector and HIV/AIDS in Africa: taking stock of 6 years of applied research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00555.X